GIC invests $1bn in Grifols’ subsidiary Biomat USA
Spanish healthcare company Grifols announced that Singapore’s wealth fund GIC agreed to invest about $1bn in Grifols’ wholly owned US subsidiary Biomat USA. As part of the definitive
Exegenesis Bio and Modalis Therapeutics have entered a research partnership and licence agreement to progress MDL-201, a therapeutic candidate for Duchenne muscular dystrophy (DMD).
Global biopharmaceutical firm Sanofi has launched a dedicated vaccines mRNA Center of Excellence to accelerate development and delivery of next-generation vaccines. The company has also announced plans to